IGC Pharma Inc
For the period ended Mar 31, 2025. Filed Jun 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 27, 2025
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Years Ended March 31, | ||||
|---|---|---|---|---|
| 2025 ($) | 2024 ($) | |||
| Cash flows from operating activities: | ||||
| Net loss | (7,121) | (13,000) | ||
| Adjustment to reconcile net loss to net cash: | ||||
| Depreciation and amortization | 618 | 637 | ||
| Provision for bad debt | 13 | 93 | ||
| Impairment of assets | 152 | 3,448 | ||
| Common stock-based compensation and expenses, net | 1,640 | 1,773 | ||
| Profit/Loss on sale of fixed assets, net | (25) | (44) | ||
| Changes in: | ||||
| Accounts receivables, net | (8) | (25) | ||
| Inventory | 180 | 1,008 | ||
| Deposits and advances | (187) | 150 | ||
| Claims and advances | 7 | 315 | ||
| Accounts payable | 106 | 243 | ||
| Accrued and other liabilities | (196) | 197 | ||
| Operating lease asset | 100 | 129 | ||
| Operating lease liability | (74) | (123) | ||
| Net cash used in operating activities | (4,795) | (5,199) | ||
| Cash flow from investing activities: | ||||
| Purchase of property, plant, and equipment | (112) | (138) | ||
| Sale of property, plant, and equipment | 40 | 44 | ||
| Proceeds from short-term investments | - | 154 | ||
| Acquisition and development of intangible assets | (370) | (377) | ||
| Net cash used in investing activities | (442) | (317) | ||
| Cash flows from financing activities: | ||||
| Net proceeds from the issuance of common stock | 4,454 | 3,027 | ||
| Proceeds from common stock subscribed | - | 500 | ||
| Repayment of long-term loan | (3) | (3) | ||
| Net cash provided by financing activities | 4,451 | 3,524 | ||
| Effects of exchange rate changes on cash and cash equivalents | (7) | (6) | ||
| Net decrease in cash and cash equivalents | (793) | (1,998) | ||
| Cash and cash equivalents at the beginning of the period | 1,198 | 3,196 | ||
| Cash and cash equivalents at the end of the period | 405 | 1,198 | ||
| Supplementary information: | ||||
| Non-cash items: | ||||
| Common stock issued/granted for stock-based compensation, including patent acquisition | 1,640 | 1,773 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.